Table 2 Crude infection rates for each medication initiation cohort
Medication exposure | Person-years of follow-up | Number of infections | Infection rate per 100 person-years (95Â % CI) |
|---|---|---|---|
MTX | 2668.5 | 39 | 1.46 (1.07–2.00) |
TNFi monotherapy | 2144.0 | 33 | 1.54 (1.09–2.17) |
TNFi + MTX combination | 1094.5 | 19 | 1.74 (1.11–2.72) |
Anakinra with or without MTX | 225.9 | 19 | 8.41 (5.36–13.2) |
MTX with SJIA | 113.7 | 3 | 2.64 (0.85–8.18) |
Etanercept | 2594.0 | 37 | 1.43 (1.03–1.97) |
Adalimumab | 413.2 | 12 | 2.90 (1.65–5.11) |
Infliximab | 227.1 | 3 | 1.32 (0.43–4.10) |